Ukr.Biochem.J. 2024; Том 96, № 4, липень-серпень, c. 17-24

doi: https://doi.org/10.15407/ubj96.04.017

Рівні гормонів міонектину, іризину, апеліну-13 та Елабели як біомаркерів цукрового діабету 2 типу: систематичний огляд

04.04.2025   Uncategorized   No comments

Abdullah A. H. Al-Rubaye1*, Walaa E. Jasim2, Ahmed A. H. Mohsin2

1Department of Medical Laboratory Technology, College of Health
and Medical Technology, Southern Technical University, Basra, Iraq;
2Department of Medical Laboratory Technology, College of Health
and Medical Technology, Middle Technical University, Baghdad, Iraq;
*e-mail: abdulla.abbas@stu.edu.iq

Отримано: 16 травня 2024; Виправлено: 23 червня 2024;
Затверджено: 25 липня 2024; Доступно онлайн: 04 вересня 2024

Резистентність до інсуліну вважається ключовим патофізіологічним показником, що лежить в основі цукрового діабету 2 типу. Проте, його патофізіологія залишається складною і недостатньо зрозумілою. Було показано, що міокіни, такі як міонектин та іризин, вироблені м’язовою тканиною, впливають на чутливість до інсуліну та можуть відігравати істотну роль в етіології резистентності до інсуліну. Апелін і Елабела, ендогенні пептидні ліганди рецептора протеїну J ангіотензину II (APJ), активно беруть участь у контролі метаболізму ліпідів і глюкози, що вказує на їхню важливу роль у лікуванні метаболічних станів, таких як діабет 2 типу. У цьому огляді проаналізовано дані щодо рівня маркерів резистентності до інсуліну – міонектину, іризину, апеліну-13 та Елабели – у пацієнтів із цукровим діабетом 2 типу.

Ключові слова: , , , , ,

Посилання:

  1. Hamzah Al-Rubaye AA. The correlation between type 2 diabetes mellitus and hypertension in Iraqi patients. J Med Chem Sci. 2023;6(4):778-788. CrossRef
  2. Xuan X, Lin J, Zhang Y, Zhou L, Xu L, Jia J, Zhao B, Lin Z , Zhu Q, Li L, Wu T, Zhang S, Jiang H, Wang Y. Serum irisin levels and clinical implication in elderly patients with type 2 diabetes mellitus. J Clin Med Res. 2020;12(9):612-617. PubMed, PubMedCentral, CrossRef
  3. Ahmed Mahdi Habeeb, Atta Ah Mousa Al-Sarray, Ali Hussein Al Hafidh, Rafah Sabah Barrak, Afraa Brahim. Assessment of vitamin D3 level among a sample of type 2 diabetic patients attending diabetes and endocrinology center in Al-Hilla city. J Tech. 2023;5(3):207-212. CrossRef
  4. Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576(7785):51-60. PubMed, CrossRef
  5. Safa Nadhum Mohammed, Walaa Esmael Jassim, Najah Ali Mohammed. To investigate the associations of dyslipidemia and BMI, as risk factors leading to insulin resistance and development of type2 diabetes mellitus in Baqubah city. J Techn. 2022;4(3):27-33. CrossRef
  6. Malone JI, Hansen BC. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite? Pediatr Diabetes. 2019;20(1):5-9. PubMed, CrossRef
  7. Eizirik DL, Pasquali L, Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol. 2020;16(7):349-362. PubMed, CrossRef
  8. Jain C, Ansarullah, Bilekova S, Lickert H. Targeting pancreatic β cells for diabetes treatment. Nat Metab. 2022;4(9):1097-1108. PubMed, CrossRef
  9. Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CDA, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222. PubMed, PubMedCentral, CrossRef
  10. Li K, Liao X, Wang K, Mi Q, Zhang T, Jia Y, Xu X, Luo X, Zhang C, Liu H, Zhen H, Li L, Yang G. Myonectin Predicts the Development of Type 2 Diabetes. J Clin Endocrinol Metab. 2018;103(1):139-147. PubMed, CrossRef
  11. Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 2020;13:3611-3616. PubMed, PubMedCentral, CrossRef
  12. Stewart AN, Little HC, Clark DJ, Zhang H, Wong GW. Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly. Biochemistry. 2020;59(29):2684-2697. PubMed, PubMedCentral, CrossRef
  13. Gamas L, Matafome P, Seiça R. Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk. J Diabetes Res. 2015;2015:359159. PubMed, PubMedCentral, CrossRef
  14. Li Z, Yang YL, Zhu YJ, Li CG, Tang YZ, Ni CL, Chen LM, Niu WY. Circulating Serum Myonectin Levels in Obesity and Type 2 Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2021;129(7):528-534. PubMed, CrossRef
  15. Al-Regaiey KA, Habib SS, Alhaqbani AO, Alhamed MS, Alsalman MA, Alhadlaq AA, Alassaf FS, Alrayes BK, Alyami RM, Iqbal M. Decreased plasma myonectin levels in female patients with type 2 diabetes mellitus and its correlation with lipid and glycemic parameters. Eur Rev Med Pharmacol Sci. 2023;27(18):8773-8779. PubMed, CrossRef
  16. Leiherer A, Muendlein A, Geiger K, Saely CH, Larcher B, Mader A, Maechler M, Sprenger L, Mutschlechner B, Benda, Fraunberger P, Drexel H. The new myokine myonectin is significantly associated with type 2 diabetes in elderly patients. Circulation. 2021;144(Suppl 1): A8938-A8938. CrossRef
  17. Sun H, Li Z, Hu W, Ma W. Association of serum and aqueous humor myonectin concentrations with diabetic retinopathy. Sci Rep. 2021;11(1):7215. PubMed, PubMedCentral, CrossRef
  18. Hashim HA, Al-Shammaa NMJ. Study of Irisin Level Hormone and Some Biochemical Parameters in Iraqi Diabetic Type 2 without Hypothyroidism. Pakistan J Med Health Sci. 2022;16(06):403-406. CrossRef
  19. Mahmoodnia L, Sadoughi M, Ahmadi A, Kafeshani M. Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients. J Renal Inj Prev. 2016;6(2):88-92. PubMed, PubMedCentral, CrossRef
  20. Ibrahim IH, Salih SF. Serum irisin in individuals with type 2 diabetes Mellitus and prediabetes in Duhok City. J Life Bio Scie Res. 2022;3(02):59-64. CrossRef
  21. Jassim NA. Estimation of Irisin and Some Biochemical Parameters in Diabetes Mellitus Iraqi Patients. J Med Chem Sci. 2023;6(4):809-815. CrossRef
  22. Chachan TAK A, Huda Farhan, Shatha Hamed. Determination of Irisin, Body Mass Index, and Other Biochemical Parameters in a Sample of Iraqi Type II Diabetic Patients. J Tech. 2022;4(3):53-59. CrossRef
  23. Mathia VL, Mendonça MIS, Simões DP, Perez MM, Alves BDCA, Encinas JFA, Raimundo JRS, Arcia CGC, Murad N, Fonseca FLA, Veiga GLD. Relationship of irisin expression with metabolic alterations and cardiovascular risk in type 2 diabetes mellitus: a preliminary study. Rev Assoc Med Bras. 2023;69(12):e20230812. PubMed, PubMedCentral, CrossRef
  24. Gao Z, Zhong X, Tan YX, Liu D. Apelin‑13 alleviates diabetic nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis. Int J Mol Med. 2021;48(3):175. PubMed, PubMedCentral, CrossRef
  25. Li C, Cheng H, Adhikari BK, Wang S, Yang N, Liu W, Sun J, Wang Y. The Role of Apelin-APJ System in Diabetes and Obesity. Front Endocrinol (Lausanne). 2022;13:820002. PubMed, PubMedCentral, CrossRef
  26. Fan Y, Zhang Y, Li X, Zheng H, Song Y, Zhang N, Shen C, Fan X, Ren F, Shen J, Ren G, Yang J. Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus. Drug Des Devel Ther. 2015;9:4679-4683. PubMed, PubMedCentral, CrossRef
  27. Palmer ES, Irwin N, O’Harte FP. Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An Update. Clin Med Insights Endocrinol Diabetes. 2022;15:11795514221074679. PubMed, PubMedCentral, CrossRef
  28. Hu G, Wang Z, Zhang R, Sun W, Chen X. The Role of Apelin/Apelin Receptor in Energy Metabolism and Water Homeostasis: A Comprehensive Narrative Review. Front Physiol. 2021;12:632886. PubMed, PubMedCentral, CrossRef
  29. Shin K, Pandey A, Liu XQ, Anini Y, Rainey JK. Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity. FEBS Open Bio. 2013;3:328-333. PubMed, PubMedCentral, CrossRef
  30. Jaid HK, Khaleel FM, Salman IN, Baydaa Ahmed Abd. Estimation of apelin levels in Iraqi patients with Type II diabetic peripheral neuropathy. Baghdad Sci J. 2023;20(5):1684-1684. CrossRef
  31. Chen H, Wang L, Wang W, Cheng C, Zhang Y, Zhou Y, Wang C, Miao X, Wang J, Wang C, Li J, Zheng L, Huang K. ELABELA and an ELABELA Fragment Protect against AKI. J Am Soc Nephrol. 2017;28(9):2694-2707. PubMed, PubMedCentral, CrossRef
  32. Ma Z, Song JJ, Martin S, Yang XC, Zhong JC. The Elabela-APJ axis: a promising therapeutic target for heart failure. Heart Fail Rev. 2021;26(5):1249-1258. PubMed, PubMedCentral, CrossRef
  33. Liu Y, Wang L, Shi H. The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia. Hypertens Res. 2019;42(7):928-934. PubMed, CrossRef
  34. Karagoz ZK, Aydin S, Ugur K, Tigli A, Deniz R, Baykus Y, Sahin I, Yalcin MH, Yavuz A, Aksoy A, Aydin S. Molecular communication between Apelin-13, Apelin-36, Elabela, and nitric oxide in gestational diabetes mellitus. Eur Rev Med Pharmacol Sci. 2022;26(9):3289-3300. PubMed, CrossRef
  35. Shelbaya S, Abu Shady MM, Nasr MS, Bekhet MM, Mageed YA, Abbas M. Study of Irisin Hormone Level in Type 2 Diabetic Patients and Patients with Diabetic Nephropathy. Curr Diabetes Rev. 2018;14(5):481-486. PubMed, CrossRef
  36. Kahla H, Hussein MAK, Taha N, Hany AM, Youssry M. Association between irisin and vascular complications of type 2 diabetic patients: a prospective case–control study. Egypt J Intern Med. 2024;36(1):15. CrossRef
  37. Onalan E, Doğan Y, Onalan E, Gozel N, Buran I, Donder E. Elabela levels in patients with type 2 diabetes: can it be a marker for diabetic nephropathy? Afr Health Sci. 2020;20(2):833-840. PubMed, PubMedCentral, CrossRef
  38. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, Garcia-Arnes J, Tinahones FJ, Garcia-Fuentes E. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg. 2009;19(11):1574-1580. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.